BioSpace News Archive

Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications.

PhaseBio Pharmaceuticals, Inc. today announced the complete results from its Phase 2b clinical trial of bentracimab that were presented on April 2nd during a Late Breaking Featured Clinical Research Presentation at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22).

Alzamend Neuro, Inc. today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board.

Oramed Pharmaceuticals Inc. today announced the appointment of Yadin Rozov to its Board of Directors effective April 1, 2022.

Lucid Diagnostics Inc. today announced that a newly updated American College of Gastroenterology (“ACG”) clinical guideline supports esophageal precancer (“Barrett’s Esophagus”, “BE”) screening to prevent highly lethal esophageal cancer (“EAC”) utilizing its EsoGuard® DNA Test on samples collected with its EsoCheck® Cell Collection Device.

Vaxcyte, Inc. announced today that the first participants were dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical study evaluating VAX-24 for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults.

eGenesis today announced the appointment of Eliezer Katz, M.D., FACS, as Chief Medical Officer (CMO).

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, announced that members of Journey Medical’s management team will participate in the two-day Fortress Biotech Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022.

Dyadic International, Inc. today announced that its management and representatives will be presenting at the following scientific medical meetings.

Telix Pharmaceuticals Limited announces that its prostate cancer imaging agent, Illuccix®, also known as 68Ga-PSMA-11 injection, is now commercially available in the United States.